Trial Profile
A Phase I, unicentric, open and dose escalation clinical trial to evaluate the safety and the activity of the oncolytic adenovirus VCN-01 in patients with refractory retinoblastoma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs VCN 01 (Primary)
- Indications Retinoblastoma
- Focus Adverse reactions
- 29 Mar 2022 Planned End Date changed from 30 Apr 2021 to 30 Jun 2022.
- 29 Mar 2022 Planned primary completion date changed from 30 Sep 2020 to 30 Jun 2022.
- 18 Aug 2017 New trial record